KIORA PHARMACEUTICALS INC (KPRX)       0.147  -0.01 (-5.16%)

0.147  -0.01 (-5.16%)

US49721T1016 - Common Stock - Premarket: 0.1489 +0 (+1.29%)


Fundamental Rating

Taking everything into account, KPRX scores 1 out of 10 in our fundamental rating. KPRX was compared to 264 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of KPRX have multiple concerns. KPRX has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating


KPRX has negative profitability rations, so we won't be analyzing them here.
KPRX's Return On Assets of -83.66% is worse than the rest of the industry. The industry average Return On Assets is -37.75%. 81% of the industry peers have a better Return On Assets.

The Piotroski-F score of KPRX is 2.00. This is a very weak score and indicates problems in health and profitability for KPRX.
VS Industry

ROA (-83.66%) VS Industry: 19% outperformed.

-838.18
81.41

Valuation

Valuation Rating


When comparing the current price to the book value of KPRX, it is valued rather cheaply. It is trading at 0.17 times its book value.
Compared to an average industry price book ratio of 1.90, KPRX is valued rather cheaply. On top of this, KPRX is cheaper than 100% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 6.38, KPRX is valued rather cheaply. On top of this, KPRX has a better ratio than 82% of the companies listed in the same industry.

KPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPRX. No positive earnings are expected for the next year.
VS Industry

Price/Book (0.17) VS Industry: 100% outperformed.

117.15
0.17

Enterprise Value/ EBITDA (0.28) VS Industry: 82% outperformed.

886,335.20
0.01

Growth

Growth Rating


The Earnings Per Share has grown by an nice 19.25% over the past year.
Based on estimates for the next 5 years, KPRX will show a small growth in Earnings Per Share. The EPS will grow by 8.89% on average per year.

KPRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 19.25% 50.28% 22.96% 17.34% 8.89%
RevenueN/A N/A -100% N/A N/A N/A N/A

Health

Health Rating


KPRX has a Current Ratio of 2.60. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.60 indicates that KPRX has no problem at all paying its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 3.43.
The Debt to Equity ratio of KPRX is in line with the industry averages.

When comparing the Current Ratio of KPRX to the average industry Current Ratio of 3.93, KPRX is less able to pay its short term obligations than its industry peers.
KPRX has an Altman-Z score of -12.22. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.01, KPRX is in worse financial state than most of its industry peers. 92% of its industry peers have a better Altman-Z score.
KPRX has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for KPRX.
VS Industry

Debt/Equity (0) VS Industry: 55% outperformed.

15.82
0.00

Quick Ratio (2.6) VS Industry: 43% outperformed.

0.08
201.08

Current Ratio (2.6) VS Industry: 36% outperformed.

0.11
201.08

Altman-Z (-12.22) VS Industry: 8% outperformed.

-264.33
625.01

Dividend

Dividend Rating


KPRX does not give a dividend.

KPRX Daily chart

KIORA PHARMACEUTICALS INC0.147

NASDAQ:KPRX (8/16/2022, 7:00:03 PM)-0.01 (-5.16%)

Premarket: 0.1489 +0 (+1.29%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 08-12 2022-08-12/bmo Earnings (Next) 11-14 2022-11-14
Ins Owners 0.97% Inst Owners 64.16%
Market Cap 1.92M Analysts 82.5
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.17
EV/EBITDA 0.28
Profitability
ROA -83.66% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y 19.25% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 27.03%
EPS Next Y 50.28% EPS Next 2Y 22.96%
EPS Next 3Y 17.34% EPS Next 5Y 8.89%
Revenue growth 1Y -100% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 2.6 Quick Ratio 2.6
Altman-Z -12.22 F-Score 2
Debt/Equity 0
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA